Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002475|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : July 10, 2013
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor cells. Chemotherapy combined with vaccine therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide with tumor cell vaccine in treating patients who have metastatic cancer or cancer at high risk of recurrence.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Colorectal Cancer Kidney Cancer Lung Cancer Malignant Mesothelioma Pancreatic Cancer||Biological: allogeneic tumor cell vaccine Biological: autologous tumor cell vaccine Biological: recombinant interferon alfa Biological: recombinant interferon gamma Biological: sargramostim Drug: cyclophosphamide||Phase 2|
- Determine the safety and clinical effects of autologous or allogeneic active-specific intralymphatic immunotherapy with a vaccine containing interferon alfa or interferon gamma-treated tumor cells followed by sargramostim (GM-CSF) in patients with advanced cancer.
OUTLINE: This is a pilot study. Patients are stratified by tumor type.
Tumor tissue is removed from the patient and incubated with interferon alfa or interferon gamma for 72-96 hours. (If autologous tumor cells are not available, an allogeneic vaccine is prepared.) Harvested activated cells are irradiated immediately prior to use.
Patients receive cyclophosphamide IV. 48-72 hours after cyclophosphamide administration, patients receive tumor cell vaccine intradermally. Patients also receive sargramostim (GM-CSF) subcutaneously prior to vaccine administration and once daily for the next 8 days. Treatment repeats every 2 weeks for 3 courses in the absence of unacceptable toxicity. Patients with responding or stable disease after completion of course 3 may receive additional courses.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 18-24 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Official Title:||A Trial of Active Intralymphatic Immunotherapy With Interferon-Treated Cells and Cyclophosphamide|
|Study Start Date :||April 1991|
|Actual Primary Completion Date :||December 2007|
|Actual Study Completion Date :||June 2009|
- Clinical response (patients with evaluable disease)
- Duration of response (patients with evaluable disease)
- Survival (patients with evaluable disease)
- Time to recurrence (patients without evaluable disease)
- Survival (patients without evaluable disease)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002475
|United States, California|
|St. Vincent Medical Center - Los Angeles|
|Los Angeles, California, United States, 90057-1901|
|Study Chair:||Charles L. Wiseman, MD, FACP|